Scilex Holding Company Secures Tranche Investment in Datavault AI
Palo Alto, California - Scilex Holding Company (NASDAQ: SCLX), a leading innovator in pain management solutions, announced the successful closure of its initial investment tranche in Datavault AI Inc. (NASDAQ: DVLT). This strategic move underlines Scilex's commitment to advancing non-opioid pain management therapies.
Investment Overview
The initial tranche of this investment involves an injection of $150 million in Bitcoin (BTC), which is expected to yield approximately 278,914,094 shares of Datavault common stock. At the effective purchase price of $0.5378 per share, the initial acquisition includes 15,000,000 shares, with further shares contingent upon stockholder approval and a second tranche through a pre-funded warrant.
Purpose of Investment
Scilex focuses on developing and commercializing innovative, non-opioid solutions to meet the significant demands in pain management for both acute and chronic conditions. The partnership with Datavault AI aligns with their goal of addressing the large unmet needs in patient care regarding pain management and various diseases such as neurodegenerative and cardiometabolic conditions.
About Scilex Holding Company
Scilex is dedicated to creating non-opioid therapeutics that improve patient outcomes. Its product portfolio includes:
ZTlido®
This prescription lidocaine topical system is FDA-approved to treat neuropathic pain associated with postherpetic neuralgia.
ELYXYB®
As an innovative, ready-to-use oral solution, ELYXYB® can treat migraines in adults effectively, offering a much-needed option for sufferers.
Gloperba®
The only liquid oral version of colchicine is approved for preventing painful gout flares, thus ensuring patients have access to essential treatments.
Product Development Pipeline
Scilex also has product candidates, including:
SP-102 (SEMDEXA)
This novel corticosteroid gel aims to alleviate lumbosacral radicular pain. After completing its Phase 3 study, SEMDEXA received Fast Track status from the FDA.
SP-103
A next-generation formulation of ZTlido designed for treating acute pain, currently demonstrating promise as it recently completed a Phase 2 trial.
SP-104
This is a low-dose naltrexone formulation aimed at fibromyalgia treatment, showcasing Scilex's innovative edge in pain management.
About Datavault AI Inc.
Datavault AI™ leads in AI-driven data experiences and monetization. Through its cloud-based platform, it offers solutions across sectors such as biotech, fintech, and healthcare.
The company’s pioneering technologies include WiSA®, ADIO®, and Sumerian®, setting industry standards in wireless HD sound transmission and data analytics.
Conclusion
The partnership between Scilex and Datavault AI signifies not just a strategic investment but a shared vision of enhancing patient care through innovative solutions. Both companies are set to make significant contributions to their respective fields, boosting efficiency and improving patient outcomes with their cutting-edge products.
Frequently Asked Questions
What is the main focus of Scilex Holding Company?
Scilex specializes in developing and commercializing non-opioid pain management products aimed at treating acute and chronic pain.
How much did Scilex invest in Datavault AI?
Scilex invested an initial $150 million in Bitcoin in Datavault AI as part of a broader investment strategy.
What products does Scilex offer?
Scilex's product lineup includes ZTlido®, ELYXYB®, and Gloperba®, all aimed at improving patient pain management.
What are Scilex's future plans regarding product development?
Scilex has several product candidates in development, aimed at addressing various forms of pain and enhancing patient outcomes through innovative therapies.
Where is Scilex Holding Company headquartered?
Scilex is headquartered in Palo Alto, California, overseeing its mission to advance non-opioid pain management solutions.
